Strides Pharma Science Ltd gets EIR from USFDA on continued GMP status for the facility in Alathur, Chennai

Strides Alathur Private Limited, a wholly owned subsidiary of Strides Pharma Science Limited (Strides) has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its formulations facility at Alathur, Chennai thereby successfully concluding the Good Manufacturing Practices (GMP) inspection conducted between April 1-5, 2024. USFDA has determined that the inspection classification of this facility is "Voluntary Action Indicated" (VAI).

Strides Alathur facility caters to the U.S. and Other Regulated Markets. The facility manufactures tablets & capsules and supports several current and future products for the US markets.

Strides remains committed to the highest standards of compliance and will continue to focus on manufacturing high-quality pharmaceutical products for the Global markets.

Shares of Strides Pharma Science Limited was last trading in BSE at Rs. 1275.35 as compared to the previous close of Rs. 1313.65. The total number of shares traded during the day was 40369 in over 2977 trades.

The stock hit an intraday high of Rs. 1339.90 and intraday low of 1257.00. The net turnover during the day was Rs. 52338483.00.

Source : Equity Bulls

Keywords

StridesPharmaScience INE939A01011 StridesAlathur USFDA EIR FormulationsFacility